Advances in the study of berberine and its derivatives

Yaoxue Xuebao

Volumn 43, Issue 8, 2008, Pages 773-787

  Li, Bo ^a   Zhu, Wei Liang ^b   Chen, Kai Xian ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Berberine; Derivatives; Drug design; Natural product; Structure activity relationship

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BERBERINE; DRUG DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL; APOPTOSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFECT; HUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ALZHEIMER DISEASE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BERBERINE; CARDIOVASCULAR DISEASES; CELL LINE, TUMOR; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50249154389     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Dubois RN, Abramson SB, Crofford L. Cyclooxygenase in biology and disease [J]. FASEB J, 1998,12:1063-1073.
2. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice [J]. Nat Med, 1998,4:1053-1057.
3. 2+ pathway in human colon cell line [J]. Chin Pharm Bull, 2005,21:950-953.
4. Fukuda K, Hibiya Y, Mutoh M, et al. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells [J]. J Ethnopharmacol, 1999,66:227-233.
5. Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism [J]. Biol Chem, 1995,270:21429-21432.
6. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice [J]. Pharm Pharmacol, 2001,53:763-768.
7. Letasiova S, Jantova S, Miko M, et al. Effect of berberine on proliferation, biosynthesis of macromolecules, cell cycle and induction of intercalation with DNA, dsDNA damage and apoptosis in Ehrlich ascites carcinoma cells [J]. J Pharm Pharmacol, 2006,58:263-270.
8. Lin CC, Lin SY, Chung JG, et al. Down-regulation of cyclin B1 and up-regulation of Weel by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle [J]. Anticancer Res, 2006,26:1097-1104.
9. Pereira GC, Branco AF, Matos JA, et al. Mitochondrially targeted effects of berberine on K1735-M2 mouse melanoma cells comparison with direct effects on isolated mitochondrial fractions [J]. J Pharmacol Exp Ther, 2007,323:636-649.
10. Wu LT, Tsou MF, Ho CC, et al. Berberine inhibits arylamine N-acetyltransferase activity and gene expression in Salmonella Typhi [J]. Curr Microbiol, 2005: 51: 255-261.
11. Wartenberg M, Budde P, De Marees M, et al. Inhibition of tumor induced angiogenesis and matrix metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional Chinese medicine [J]. Lab Invest, 2003,83:87-98.
12. Chang KS. Down-regulation of c-Ki-ras gene expression associated with morpho logic differentiation in human embryonal carcinoma cells treated with berberine [J]. Formos Med Assoc, 1991,90:10-14.
13. Yao BT, Wu M, Wang B. Effect of berberine on gastric precancerous lesions in rats and its mechanism [J]. Chin J Integr Tradit West Med Gastro-spleen, 2005,13:81-84.
14. Wu HL, Hsu CY, Liu WH, et al. Berberine induced apoptosis of human leukemia HL-60 cells is associated with downregulation of nucleophosmin/B23 and telomerase activity [J]. Int J Cancer, 1999,81:923-929.
15. Barreto MC, Pinto RE, Arrabaca JD, et al. Inhibition of mouse liver respiration by Chelidonium majus isoquinoline alkaloids [J]. Toxicol Lett, 2003,146:37-47.
16. Jantova S, Cipak L, Letasiova S. Berberine induces apoptosis through a mitochondrial/caspase pathway in human promonocytic U937 cells [J]. Toxicol In Vitro, 2007,21:25-31.
17. Kuo CL, Chi CW, Uu TY. The anti-inflammatory potential of berberine in vitro and in vivo [J]. Cancer Lett, 2004,203:127-137.
18. Lin S, Tsai SC, Lee CC, et al. Berberine inhibits HIF-1 alpha expression via enhanced proteolysis [J]. Mol Pharmacol, 2004,66:612-619.
19. Peng PL, Hsieh YS, Wang CJ. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2 [J]. Toxicol Appl Pharmacol, 2006,214:8-15.
20. Fizuka N, Hazama S, Yoshimura K, et al. Anticachectic effects of the natural herb rhizoma coptidis and berberine on mice bearing colon 26/clone 20 adenecarcinoma [J]. Int J Cancer, 2002,99:286-291.
21. Huang LQ, Xu CF, Zhou SW, et al. Antitumor experiment research of berberine [J]. Chin Pharmacol Bull, 1997,13:189.
22. Tan HM. Five cases of diabetes treated by hydrochloricberberine [J]. Her Med, 1996,15:297.
23. Chen HF, Cai FN. Clinical investigation for 44 cases of gerontism type II diabetes treated by berberine [J]. Jiangxi J Tradit Chin Med, 1999,30:19.
24. Zhang M, Yu FH, Ding XP. Clinical investigation of type II diabetes treated by berberine [J]. Hubei J Tradit Chin Med, 2001,23:16.
25. Huo Y, Cen DZ, Tu ZL. Clinical observation on berberine in reducing blood glucose [J]. Hebei Med J, 2002,24:93-94.
26. Wei J, Wu JD, Jiang JD. Clinical study on improvement of type II diabetes mellitus complicated with fatty liver treated by berberine [J]. Chin J Integr Tradit West Med Liver Dis, 2004,14:334-336.
27. Yin J, Hu RM, Cen MD, et al. Comparision of glycoconsumption for Hep G2 cells treated by dimethylbiguanide, troglitazone and berberine [J]. Chin J Endocrinol Metab, 2002,18:488-489.
28. Yin J, Hu R, Chen M, et al. Effects of berberine on glucose metabolism in vitro [J]. Metabolism, 2002,51:1439-1443.
29. Zhou LB, Chen MD, Song HD. Mechanism research of glucose transport of adipocyte treated by berberine [J]. Chin J Endocrinol Metab, 2003,19:479-482.
30. Cheng Z, Pang T, Gu M. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK [J]. Biochim Biophys Acta, 2006,1760:1682-1689.
31. Zhou L, Yang Y, Wang X. Berberine stimulates glucose transport through a mechanism distinct from insulin [J]. Metabolism, 2007,56:405-412.
32. Li XJ. Prospect of insulin resistance and insulin resistance syndrome [J]. Chin J Endocrinol Metab, 2000,16:274-275.
33. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys [J]. Diabetes, 2001,50:1126-1133.
34. Gu Wei, Zeng WH, Hu HY. Effects of berberine on adiponectin mRNA expression in 3T3-L1 adipocyte [J]. China J Chin Mater Med, 2005,30:286-288.
35. Yun SL, Woo SK, Kang HK, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states [J]. Diabetes, 2006,55:2256-2265.
36. Kim SH, Shin EJ, Kim ED, et al. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes [J]. Biol Pharm Bull, 2007,30:2120-2125.
37. Huang C, Zhang Y, Gong Z. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway [J]. Biochem Biophys Res Commun, 2006,348:571-578.
38. Pan GY, Wang GJ, Sun JG, et al. Inhibitory action of berberine on glucose absorption [J]. Acta Pharm Sin , 2003,38:911-914.
39. Pan GY, Huang ZJ, Wang GJ, et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption [J]. Planta Med, 2003,69:632-636.
40. Campbell LK, Baker DE, Campbell RK. Miglitol, assessment of its role in the treatment of patients with diabetes mellitus [J]. Ann Pharmacother, 2000, 34:1291-1301.
41. Duan YJ, Wang SY, San LYZ, et al. Inhibition of five Chinese traditional medicines for proteinglycosylation without enzyme [J]. Chin J Diabetes, 1998,6:227-229.
42. Lee HS. Rat lens aldose reductase inhibitory activities of Coptis japonica root-derived isoquinoline alkaloids [J]. J Agric Food Chem, 2002,50:7013-7016.
43. Wang L, Zhang M, Zang DL. Effect of THB on β-receptor [J]. Acta Acad Med Qingdao, 1995,31:188-190.
44. Li BX, Yang BF, Zhou J, et al. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes [J]. Acta Pharmacol Sin, 2001,22:125-131.
45. Huang K, Dai GZ, Li XH, et al. Blocking L-calcium current by 1-tetrahydropalmatine in single ventricular myocyte of guinea pigs [J]. Acta Pharmacol Sin, 1999,20:907-911.
46. Wang YX, Zheng YM. Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine [J]. J Cardiovasc Pharmacol, 1997,30:214-222.
47. Zhu L, Zhao RR, Wang WZ. Comparative studies on the characteristics of dopamine receptors in different vascular systems [J]. Chin J Physiol Sci, 1995,11:79-86.
48. Zhang WF, Zhi JM, Guo W. Effects of tetrahydroberberine on peripheral vascular dopamine DA_1 and DA_2 receptor subtypes [J]. China J Chin Mater Med, 2000,25:497-500.
49. Wang WY, Chen KM, Guan YY, et al. Effect of berberine hydrochloride on muscarinic receptors [J]. Acta Pharm Sin, 1999,34:260-263.
50. Zhao HP, Hong Y, Xie JD, et al. Effect of berberine on left ventricular remodeling in renovascular hypertensive rats [J]. Acta Pharm Sin, 2007,42:336-341.
51. Zhao HP, Hong Y, Xie JD, et al. Influence of berberine on cardiovascular function in rats with HCM induced by L-thyroxin [J]. J Beijing Univ Tradit Chin Med, 2007,30:105-108.
52. Liang KW, Ting CT, Yin SC. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury [J]. Biochem Pharmacol, 2006,71:806-817.
53. Lee S, Lim HJ, Park HY. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model [J]. Atherosclerosis, 2006,186:29-37.
54. Werner N, Nickening G. AT1 receptor in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis [J]. Eur Heart J Supplem, 2003, 5 (Suppl A):9-13.
55. He GH, Zhou L, Wang YF. The Effect of berberine on the angiotensin II receptor type 1 in the prevention of carotid artery atherosclerosis in rabbits [J]. Chin J Arterioscler, 2006,14:1035-1037.
56. Chu ZL, Huang CG, Xu ZP. Study of platelet aggregation affected by 8 classical recipes in rabbit [J]. Chin J Integr Tradit Chin West Med, 1994,14:510-512.
57. Huang CG, Chu ZL, Wei SJ, et al. Effect of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells [J]. Thromb Res, 2002,106:223-227.
58. Wei J, Jiang JD, Wu JD. Research on the effective improvement of hyperlipidemia by berberine [J]. Chin J Diabetes, 2005,13:49-51.
59. Gou YH, Zong YX. Fifty-nine cases of hyperlipemia treated by berberine [J]. PLA Med, 1995, 2:35-36.
60. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins [J]. Nat Med, 2004, 10:1344-1351.
61. Yin J, Chen MD, Yang Y, et al. Effects of berberine on lipid metabolism in rats [J]. Acta Univ Med Second Shanghai, 2003,23:28-30.
62. He MK, Lu FE, Wang KF, et al. Effect and mechanisms of berberine on hyperlipidemic and insulin resistant rats [J]. Chin J Hosp Pharm, 2004, 24:389-391.
63. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine [J]. J Lipid Res, 2006,47:1281-1289.
64. Abidi P, Zhou Y, Jiang JD, et al. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine [J]. Arterioscler Thromb Vasc Biol, 2005,25:2170-2176.
65. Lee S, Lim HJ, Park JH, et al. Berberine-induced LDLR up-regulation involves JNK pathway [J]. Biochem Biophys Res Commun, 2007,362:853-857.
66. Hao Y, Qiu QY, Wang JJ, et al. Effects of berberine on IL-1 or tumour necrosis factor induced polymorphonuclear leucocyte-endothelium adhesion [J]. Chin J Pathophysiol, 2000,16:585-587.
67. Ckless K, Schlottfeldt JL, Pasqual M, et al. Inhibition of in vitro lymphocyte transformation by the isoquinoline alkaloid berberine [J]. J Pharm Pharmacol, 1995,47:1029-1031.
68. Xu LH, Liu Y, He XH. Inhibitory effects of berberine on the activation and cell cycle progression of human peripheral lymphocytes [J]. Cellul Mol Immunol, 2005, 2:295-301.
69. Hao Y, Qiu QY, Wu J, et al. Effect of berberine on lymphocyte endothelium adhesion and adhesion molecules expression [J]. Chin J Immunol, 1999,15:523-525.
70. Lee CH, Chen JC, Hsiang CY, et al. Berberine suppresses inflammatory agents-induced interleukin-lbeta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells [J]. Pharmacol Res, 2007,56:193-201.
71. Ko YJ, Lee JS, Park BC, et al. Inhibitory effects of Zoagumhwan water extract and berberine on angiotensin II-induced monocyte chemoattractant protein (MCP)-1 expression and monocyte adhesion to endothelial cells [J]. Vascul Pharmacol, 2007,47:189-196.
72. Cui HS, Hayasaka S, Zheng LS, et al. Effect of berberine on monocyte chemotactic protein-1 and cytokine-induced neutrophil chemoattractant-1 expression in rat lipopolysaccharide-induced uveitis [J]. Ophthalmic Res, 2007,39:32-93.
73. Jiang JY, Liu F. Discussion of immunifaction mechanism for antiinflammation of berberine [J]. Northwest Pharm J, 1997,12:59-60.
74. Li F, Wang HD, Lu DX. Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice [J]. Acta Pharmacol Sin, 2006,27:1199-1205.
75. Severina II, Muntyan MS, Lewis K, et al. Transfer of cationic antibacterial agents berberine, palmatine, and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane [J]. IUBMB Life, 2001,52:321-324.
76. Sriwilaijareon N, Petmitr S, Mutirangura A, et al. Stage specificity of plasmodium falciparum telomerase and its inhibition by berberine [J]. Parasitol Int, 2002,51:99-103.
77. Yang LM, Wang RR, Li JJ. Anti-HIV-1 activities of four berberine compounds in vitro [J]. Chin J Nat Med, 2007,5:225-228.
78. Wu JB. Preliminary study on antiviral activity of berberine derivate HB-13 against herpes simplex virus and its mechanisms of action [C]. Beijing: Chinese Academy of Medical Sciences and Peking Union Medical College, 2006.
79. Hayashi K, Minoda K, Nagaoka Y. Antiviral activity of berberine and related compounds against human cytomegalovirus [J]. Bioorg Med Chem Lett, 2007,17:1562-1564.
80. Wei YZ, Yao ZB, Yuan QF. Protective effect of berberine on rat hippocampus against cerebral ischemia [J]. Chin J Neuroanatomy, 1995, 11:315-322.
81. Shi YJ, Wu JF, Liu TP. Protective effects of berberine on rat cerebral ischemia [J]. J Nanjing Med Coll, 1995,15:256-259.
82. Wu JF, Wang P, Pan XX. Effect of berberine on protooncogene c-fos expression induced by focal cerebral ischemia in rats [J]. Chin J Clin Pharmacol Ther, 1998,3:1-4.
83. Yuan ZZ. Effects of geniposide, baicalin, berberine on rat cerebral microvascular endothelial cell adhesion molecules expression for ischemic-reperfusion injury by hypoxia/reoxigenation [C]. Beijing: Beijing University of Traditional Chinese Medicine, 2005.
84. Yoo KY, Hwang IK, Lim BO, et al. Berberry extract reduces neuronal damage and N-methyl-D-aspartate receptor 1 immunoreactivity in the gerbil hippocampus after transient forebrain ischemia [J]. Biol Pharm Bull, 2006,29:623-628.
85. 2+ concentration in cultured brain cells [J]. Acta Pharm Sin, 1997,32:15-18.
86. Wu JF, Liu TP. Effects of berberine on platelet aggregation and plasma levels of txb2 and 6-keto-pgfla in rats with reveksible middle cerebral arteky occlusion [J]. Acta Pharm Sin, 1995,30:98-102.
87. Asai M, Iwata N, Yoshikawa A. Berberine alters the processing of Alzheimer' s amyloid precursor protein to decrease Abeta secretion [J]. Biochem Biophys Res Commun, 2007,352:498-502.
88. Koji S, Keisuke O, Hideki T, et al. Potentiation of nerve growth factor-induced neunte outgrowth in PC12 cells by a coptidis rhizoma extract and protoberberine alkaloids [J]. Biosci Biotechnol Biochem, 2002,66:2491-2494.
89. Zhu FQ, Qian CY. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-lbeta and inducible nitric oxide synthase in the rat model of Alzheimer's disease [J]. BMC Neurosci, 2006,7:78.
90. Cho KM, Yoo ID, Kim WG. 8-Hydroxydihydrochelery-thrine and 8-hydroxydihydrosanguinarine with a potent acetylcholinesterase inhibitory activity from Chelidonium majus L [J]. Biol Pharm Bull, 2006,29:2317-2320.
91. Jin GZ, Zhou QT, Chen LJ. New pharmacological effects of tetrahydroprotoberberines on dopamine receptor [J]. Bull Natl Sci Foundat China, 2000, 300.
92. + current in acutely dissociated rat hippocampal CA1 pyramidal neurons [J]. Neurosci Lett, 1997,222:115-118.
93. Kulkarni SK, Dhir A. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride [J]. Eur J Pharmacol, 2007,569:77-83.
94. Li H, Miyahara T, Tezuka Y, et al. Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model [J]. Biol Pharm Bull, 2003, 26:110-111.
95. Nian H, Xu LL, Ma MH, et al. Effects of berberine from Cortex Phellodendri Chinensis on osteoporosis in ovariectomized rats [J]. Pharm Care Res, 2007,7:41-44.
96. Tan Y, Tang Q, Hu BR, et al. Effect of berberine on the mRNA expression of phosphodiesterase type 5 (PDE5) in rat corpus cavernosum [J]. Natl J Androl, 2004,10:890-893.
97. Tan Y, Tang Q, Hu BR, et al. Modulation action of berberine on NO-cGMP signal pathway in isolated corpus cavernosum smooth muscle [J]. Chin Pharmacol Bull, 2005,21:435-440.
98. Tan Y, Tang Q, Hu BR. Effects of berberine on cyclic GMP and cyclic AMP levels in rabbit corpus cavernosum in vitro [J]. Natl J Androl, 2005, 11:406-408.
99. Chiou WF, James C, Chen CF. Relaxation of corpus cavernosum and raised intracavernous pressure by berberine in rabbit [J]. British J Pharmacol, 1998,125:1677-1684.
100. Zhang HQ, Zou P, Wang HD. Mechanisms for protection of berberine against LPS-induced acute lung injury in mice [J]. Chin J Pathophysiol, 2007,23:495-499.
101. Pan LR, Tang Q, Fu Q. Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice [J]. Acta Pharmacol Sin, 2005,26:1334-1338.
102. Hsiang CY, Wu SL, Cheng SE. Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells [J]. J Biomed Sci, 2005,12:791-801.
103. Hwang JM, Wang CJ, Chou FP, et al. Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver [J]. Arch Toxicol, 2002,76:664-670.
104. Misík V, Bezáková L, Máleková L, et al, Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium [J]. Planta Med, 1995,61:372-373.
105. Choi DS, Kim SJ, Jung MY. Inhibitory activity of berberine on DNA strand cleavage induced by hydrogen peroxide and cytochrome c [J]. Biosci Biotechnol Biochem, 2001,65:452-455.
106. Xu X, Malavé A. Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats [J]. Pharmacol Toxicol, 2001,88:232-237.
107. Chang CK, Lin MT. DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats [J]. Neurosci Lett, 2001,307:163-166.
108. Xin HW, Wu XC, Li Q. Study on differential expression of genes associated with metabolism by cDNA microarry in rat liver treated with berberine chloride [J]. Chin Pharmacol Bull, 2004,20:1122-1126.
109. Zhang Y, Zhang L, Zhou YM. Study on pharmacological action mechanism of berberine chloride by genome-wide expression profiling of saccharomyces cerevisi [J]. Chin J Integr Tradit Chin West Med, 2003,23:48-53.
110. 1H NMR investigation of the interaction of berberine and sanguinarine with DNA [J]. Indian J Biochem Biophys, 1995,32:74-77.
111. Pilch DS, YuC, Makhey D, et al. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs [J]. Biochemistry, 1997,36:12542-12553.
112. Pal S, Kumar GS, Debnath D, et al. Interaction of the antitumour alkaloid coralyne with duplex deoxyribonucleic acid structures; spectroscopic and viscometric studies [J]. Indian J Biochem Biophys, 1998,35:321-332.
113. Mazzini S, Bellucci MC, Mondelli R, et al. Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT) (2) [J]. Bioorg Med Chem, 2003,11:505-514.
114. Chen WH, Qin Y, Cai Z, et al. Spectrometric studies of cytotoxic protoberberine alkaloids binding to double-stranded DNA [J]. Bioorg Med Chem, 2005,13:1859-1866.
115. Qin Y, Chen WH, Pang JY. DNA-binding affinities and sequence specificities of protoberberine alkaloids and their demethylated derivatives: a comparative study [J]. Chem Biodivers, 2007,4:145-153.
116. Islam MM, Sinha R, Kumar GS. RNA binding small molecules : studies on t-RNA binding by cytotoxic plant alkaloids berberine, palmatine and the comparison to ethidium [J]. Biophys Chem, 2007,125:508-520.
117. Zhao LP, Huang DY. Fluorescence characteristics of the interaction between cycle DNA plasmid pUC118 and ligand berberine [J]. J Shanxi Univ -Natl Sci Edit, 2005,28:83-86.
118. Giri P, Hossain M, Kumar GS. Molecular aspects on the specific interaction of cytotoxic plant alkaloid palmatine to poly(A) [J]. Int J Biol Macromol, 2006,39:210-221.
119. Wu JF, Chen LX, Luo GA. Interaction study between double-stranded DNA and berberine using capillary zone electrophoresis [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2006,833:158-164.
120. Chen WH, Pang JY, Qin Y, et al. Synthesis of linked berberine dimers and their remarkably enhanced DNA-binding affinities [J]. Bioorg Med Chem Lett, 2005,15:2689-2692.
121. Long YH, Bai LP, Qin Y. Spacer length and attaching position-dependent binding of synthesized protoberberine dimers to double-stranded DNA [J]. Bioorg Med Chem, 2006,14:4670-4676.
122. Franceschin M, Rossetti L, D'Ambrosio A, er al. Natural and synthetic G-quadruplex interactive berberine derivatives [J]. Bioorg Med Chem Lett, 2006,16:1707-1711.
123. Gornall KC, Samosorn S, Talib J. Selectivity of an indolyl berberine derivative for tetrameric G-quadruplex DNA [J]. Rapid Commun Mass Spectrom, 2007,21:1759-1766.
124. Das S, Kumar GS, Ray A, et al, Spectroscopic and thermodynamic studies on the binding of sanguinarine and berberine to triple and double helical DNA and RNA structures [J]. J Biomol Struct Dyn, 2003,20:703-714.
125. Su X, Qin F, Kong L, et al. Characterization of enantioselective binding of racemic natural tetrahydropalmatine to DNA by chromatographic methods [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007,845:174-179.
126. Zuo F, Nakamura N, Akao T. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry [J]. Drug Metab Dispos, 2006,34:2064-2072.
127. Zhu ZY. Investigation of metabolites of berberine in humans and in rats [C]. Shenyang: Shenyang Pharmaceutical College, 2002.
128. Pan GY, Wang GJ, Liu XD, et al. The involvement of P-glycoprotein in berberine absorption [J]. Pharmacol Toxicol, 2002,91:193-197.
129. Qu QM, Zhang MF. Pharmacokineticsof berberine [J]. Chin Acad Med Mag Organisms, 2002,4:31-35.
130. Hong Z, Fan G, Le J. Brain pharmacokinetics and tissue distribution of tetrahydropalmatine enantiomers in rats after oral administration of the racemate [J]. Biopharm Drug Dispos, 2006,27:111-117.
131. Wang GJ, Gao L, Yang P, et al. Pharmacokinetics and pharmacodynamics of 7-(4-chlorbenzyl)-7, 8, 13, 13a-tetrahydroberberine chloride in dogs [J]. Chin J Pharmacol Toxicol, 2000, 14:72-75.
132. Feng NP, Zhang ZX, An DK, et al. Analysis of the metabolite of 7-(4-chlorbenzyl)-7,8,13,13a-tetrahydroberberine in rabbit [J]. Acta Pharm Sin, 2001,36:137-139.
133. Feng NP, Zhang ZX, An DK, et al. Investigation of the metabolism of 7-(4-chlorbenzyl)-7,8,13,13a-tetrahydroberberine chloride in the rat [J]. Eur J Drug Metab Pharmacokinet, 1998,23:41-44.
134. Zeng MY, Li JM. Toxic reaction report of berberine [J]. Tradit Chin Drug Res Clin Pharmacol, 1995,6:47-48.
135. Iwasa K, Kamigauchi M, Sugiura M, et al. Antimicrobial activity of some 13-alkyl substituted protoberberinium salts [J]. Planta Med, 1997,63:196-198.
136. Iwasa K, Nanba H, Lee DU, et al. Structure activity relationships of protoberberines having antimicrobial activity [J]. Planta Med, 1998,64:748-751.
137. Iwasa K, Lee DU, Kang SI, et al. Antimicrobial activity of 8-alkayl and 8-phenyl-substituted berberines and their 12-bromo derivatives [J]. J Nat Prod, 1998,61:1150-1153.
138. Park KD, Lee JH, Kim SH, et al. Synthesis of 13-(substituted benzyl) berberine and berberrubine derivatives as antifungal agents [J]. Bioorg Med Chem Lett, 2006,16:3913-3916.
139. Yang Y, Ye XL, Li XG. Synthesis and antimicrobial activity of 8-alkylberberine derivatives with a long aliphatic chain [J]. Planta Med, 2007,73:602-604.
140. Hong SW, Kim SH, Jeun JA, et al. Antimicrobial activity of 9-O-acyl-and 9-O-benzyl-substituted berberrubines [J]. Planta Med, 2000,66:361-363.
141. Kim SH, Lee SJ, Lee JH, et al. Antimicrobial activity of 9-O-acyl- and 9-O-alkylberberrubine derivatives [J]. Planta Med, 2002,68:277-281.
142. Zheng HY. Experimental and theoretical studies of protoberberine alkaloids on the mechanism of multiple activities [C]. Tianjing: Tianjing Medical College, 2004.
143. Iwasa K, Kim HS, Wataya Y, et al. Antimalarial activity and structure activity relationships of protoberberine alkaloids [J]. Eur J Med Chem, 1998,33:65-69.
144. Colin WW, Sarah JM, Peter FR, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids [J]. J Nat Prod, 2000,63:1638-1640.
145. Iwasa K, Nishiyama Y, Ichimaru M, et al. Structure activity relationships of quaternary protoberberine alkaloids having antimalarial activity [J]. Eur J Med Chem, 1999,34:1077-1083.
146. Zhang C, Lin Y, Hua WY. Synthesis of chiral compounds of 4-chlorobenzyl tetrahydroberberine chloride [J]. J China Pharm Univ, 2004,35:393-3%.
147. Zhang C, Huang WL. Synthesis and antiarrhythmic activity of protoberberine quaternary ammonium compounds [J]. J China Pharm Univ, 2003, 34:7-12.
148. Wang RF, Xu GY, Hua WY, et al. Synthesis and antiarrhythmic activity of some tetrahydroherberine quaternary ammonium compounds [J]. Chin J Med Chem, 1996,6:243-248.
149. Feng Y, Yang L, Dai DZ. Comparison of inhibitory effects of CPU-86017 and its optical derivates on mouse blood pressure and rat aortic contraction [J]. Chin J Clin Pharmacol Ther, 2007, 12:23-27.
150. Bustanji Y, Taha MO, Yousef AM, et al. Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation [J]. J Enzyme Inhib Med Chem, 2006,21:163-171.
151. Bian X, He L, Yang G. Synthesis and antihyperglycemic evaluation of various protoberberine derivatives [J]. Bioorg Med Chem Lett, 2006,16:1380-1383.
152. Iwasa K, Moriyasu M, Yamori T, et al. In vitro cytotoxicity of the protoberberine-type alkaloids [J]. J Nat Prod, 2001,64:896-898.
153. Orfila L, Rodríguez M, Colman T, et al. Structural modification of berberine alkaloids in relation to cytotoxic activity in vitro [J]. J Nat Prod, 2000,71:449-456.
154. Kobayashi Y, Yamashita Y, Fujii N, et al. Inhibitors of DNA topoisomerase I and II isolated from the coptis rhizomes [J]. Planta Med, 1995,61:414-418.
155. Krishnan P, Bastow KF. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition [J]. Anticancer Drug Des, 2000,15:255-264.
156. Qin Y, Pang JY, Chen WH. Inhibition of DNA topoisomerase I by natural and synthetic mono- and dimeric protoberberine alkaloids [J]. Chem Biodivers, 2007,4:481-487.
157. Zhang WJ, Ou TM, Lu YJ. 9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNA [J]. Bioorg Med Chem, 2007,15:5493-5501.
158. Guo X, Wang LM, Liu J, et al. Characteristics of tetrahydroprotoberberines on dopamine D1 and D2 receptors in calf striatum [J]. Acta Pharmacol Sin, 1997,18:225-230.
159. Wang LM, Zhang XX, Jin GZ. Effects of tetrahydroprotoberberines on dopamine D2 receptors in ventral tegmental area of rat [J]. Acta Pharmacol Sin, 1997,18:143-146.
160. Fu XC, Hu YZ, Zhou QT. Quantitative structure-activity relationships for tetrahydroprotoberberines to interact with the dopamine 2 receptor [J]. Chin J Med Chem, 1999,9:111-113.
161. Lin AH, LI HY, Liu YM, et al. Preparation and release characteristics of berberine chitosan nanoparticles in vitro [J]. China Pharm, 2007,18:755-757.